AthenaHQ is a platform dedicated to Generative Engine Optimization (GEO), designed to help businesses dominate AI-driven brand discovery. The platform supports real-time monitoring of brand mentions and perception in AI-generated content, enabling businesses to refine their AI strategy. AthenaHQ integrates advanced tools for competitor analysis, AI search volume tracking, and sentiment analysis, providing businesses with crucial insights to adjust and optimize their approach. By focusing on AI readability and structured data, AthenaHQ helps brands enhance their visibility across generative search engines, positioning them for long-term success as the search landscape shifts towards AI-driven discovery.
Learn more
RegDesk stands out as the leading RIMS platform enhanced by AI, tailored specifically for Medical Device, Pharmaceutical, and IVD companies.
• Our unique Regulatory Intelligence encompasses data from over 120 countries, all presented in a uniform format, and includes timely alerts regarding regulatory updates.
• With our AI-driven Application Builder, regulatory affairs teams can efficiently create and submit global applications in a fraction of the usual time.
• The Change Assessment feature enables RA teams to evaluate the implications of changes on current products and determine the necessary actions.
• Our Distributor Collaboration tool facilitates smooth workflows for communication and document sharing with external partners.
• The Standards Management function simplifies the process for RA teams to locate and oversee both international and country-specific standards.
• Additionally, our Tracking & Reporting capability empowers teams to monitor regulatory initiatives worldwide, receive notifications for renewals, and quickly compile reports on key performance indicators.
To learn more about our offerings, please explore our website.
Learn more
NVIDIA BioNeMo
BioNeMo is a cloud-based platform designed for drug discovery that harnesses artificial intelligence and employs NVIDIA NeMo Megatron to enable the training and deployment of large biomolecular transformer models at an impressive scale. This service provides users with access to pre-trained large language models (LLMs) and supports multiple file formats pertinent to proteins, DNA, RNA, and chemistry, while also offering data loaders for SMILES to represent molecular structures and FASTA for sequences of amino acids and nucleotides. In addition, users have the flexibility to download the BioNeMo framework for local execution on their own machines. Among the notable models available are ESM-1, which is based on Meta AI’s state-of-the-art ESM-1b, and ProtT5, both fine-tuned transformer models aimed at protein language tasks that assist in generating learned embeddings for predicting protein structures and properties. Furthermore, the platform will incorporate OpenFold, an innovative deep learning model specifically focused on forecasting the 3D structures of new protein sequences, which significantly boosts its capabilities in biomolecular exploration. Overall, this extensive array of tools establishes BioNeMo as an invaluable asset for researchers navigating the complexities of drug discovery in modern science. As such, BioNeMo not only streamlines research processes but also empowers scientists to make significant advancements in the field.
Learn more
Recursion
Recursion is a pioneering TechBio company reimagining drug discovery through the integration of biology, artificial intelligence, and large-scale data. Founded more than ten years ago, Recursion introduced a novel approach that uses cellular imaging to train AI models to understand disease mechanisms. The company’s mission is to reduce the high failure rate of traditional drug development by uncovering deeper biological insights. At the core of its work is the Recursion OS, a drug discovery and development platform that unifies data, machine learning, and automated experimentation. Recursion has built one of the world’s largest proprietary biological and chemical datasets, spanning phenomics, transcriptomics, proteomics, and patient data. Its automated wet labs generate millions of experiments weekly, creating a continuous feedback loop that improves model performance. This system enables rapid identification of new drug targets and optimized molecule design. Recursion’s pipeline includes multiple programs addressing aggressive cancers and rare diseases with significant unmet needs. The company partners with pharmaceutical leaders, computational technology providers, and data innovators to extend its impact. With BioHive-2, a powerful supercomputer built with NVIDIA, Recursion processes massive datasets at unprecedented speed. These capabilities allow the company to move candidates faster from discovery to clinical trials. Overall, Recursion is focused on delivering better medicines to patients through AI-driven precision and scale.
Learn more
